These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 22736376)

  • 61. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment.
    Luo TY; Tang IC; Wu YL; Hsu KL; Liu SW; Kung HC; Lai PS; Lin WJ
    Nucl Med Biol; 2009 Jan; 36(1):81-8. PubMed ID: 19181272
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
    Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
    Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Metal-Chelating Polymers (MCPs) with Zwitterionic Pendant Groups Complexed to Trastuzumab Exhibit Decreased Liver Accumulation Compared to Polyanionic MCP Immunoconjugates.
    Liu P; Boyle AJ; Lu Y; Adams J; Chi Y; Reilly RM; Winnik MA
    Biomacromolecules; 2015 Nov; 16(11):3613-23. PubMed ID: 26469142
    [TBL] [Abstract][Full Text] [Related]  

  • 64. ²¹³Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells.
    Pickhard A; Piontek G; Seidl C; Kopping S; Blechert B; Mißlbeck M; Brockhoff G; Bruchertseifer F; Morgenstern A; Essler M
    Nucl Med Biol; 2014 Jan; 41(1):68-76. PubMed ID: 24210808
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 66. (131)I-Nimotuzumab - A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR.
    Kameswaran M; Samuel G; Dev Sarma H; Shinde SN; Dash A; Venkatesh M
    Appl Radiat Isot; 2015 Aug; 102():98-102. PubMed ID: 26002276
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Intracellular routing in breast cancer cells of streptavidin-conjugated trastuzumab Fab fragments linked to biotinylated doxorubicin-functionalized metal chelating polymers.
    Liu P; Cai Z; Kang JW; Boyle AJ; Adams J; Lu Y; Ngo Ndjock Mbong G; Sidhu S; Reilly RM; Winnik MA
    Biomacromolecules; 2014 Mar; 15(3):715-25. PubMed ID: 24506198
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.
    Breeman WA; de Jong M; Erion JL; Bugaj JE; Srinivasan A; Bernard BF; Kwekkeboom DJ; Visser TJ; Krenning EP
    J Nucl Med; 2002 Dec; 43(12):1650-6. PubMed ID: 12468515
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide.
    Capello A; Krenning EP; Breeman WA; Bernard BF; de Jong M
    J Nucl Med; 2003 Jan; 44(1):98-104. PubMed ID: 12515882
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.
    Chen P; Wang J; Hope K; Jin L; Dick J; Cameron R; Brandwein J; Minden M; Reilly RM
    J Nucl Med; 2006 May; 47(5):827-36. PubMed ID: 16644753
    [TBL] [Abstract][Full Text] [Related]  

  • 72. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1.
    Hu M; Wang J; Chen P; Reilly RM
    Bioconjug Chem; 2006; 17(5):1280-7. PubMed ID: 16984139
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
    Al-Ejeh F; Shi W; Miranda M; Simpson PT; Vargas AC; Song S; Wiegmans AP; Swarbrick A; Welm AL; Brown MP; Chenevix-Trench G; Lakhani SR; Khanna KK
    J Nucl Med; 2013 Jun; 54(6):913-21. PubMed ID: 23564760
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Synthesis of polyglutamide-based metal-chelating polymers and their site-specific conjugation to trastuzumab for auger electron radioimmunotherapy.
    Lu Y; Ngo Ndjock Mbong G; Liu P; Chan C; Cai Z; Weinrich D; Boyle AJ; Reilly RM; Winnik MA
    Biomacromolecules; 2014 Jun; 15(6):2027-37. PubMed ID: 24838009
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro.
    Eke I; Ingargiola M; Förster C; Kunz-Schughart LA; Baumann M; Runge R; Freudenberg R; Kotzerke J; Heldt JM; Pietzsch HJ; Steinbach J; Cordes N
    Int J Radiat Biol; 2014 Aug; 90(8):678-86. PubMed ID: 24597752
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease.
    Milenic DE; Garmestani K; Brady ED; Albert PS; Ma D; Abdulla A; Brechbiel MW
    Clin Cancer Res; 2004 Dec; 10(23):7834-41. PubMed ID: 15585615
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
    Reilly RM; Chen P; Wang J; Scollard D; Cameron R; Vallis KA
    J Nucl Med; 2006 Jun; 47(6):1023-31. PubMed ID: 16741313
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
    Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
    Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
    [TBL] [Abstract][Full Text] [Related]  

  • 80. (177)Lu/ (90)Y intermediate-affinity monoclonal antibodies targeting EGFR and HER2/c-neu: preparation and preclinical evaluation.
    Beckford Vera DR; Eigner S; Eigner Henke K; Leyva Montaña R; Melichar F; Beran M
    Recent Results Cancer Res; 2013; 194():301-17. PubMed ID: 22918766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.